Fundraising FoxOrganovo, Inc.
2 known investors
Find your way into Organovo, Inc.
Sign up to see every warm intro you have to Organovo, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Organovo, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Organovo develops regenerative medicine therapies using bioprinting technology to treat serious liver diseases. The company serves the pharmaceutical and biotech sectors with innovative therapeutic approaches based on decades of leadership expertise in life sciences.
Founders & leadership
KM
Keith MurphyExecutive Chairman
Investors · 2
Founder mafia
2 people who came through Organovo, Inc. went on to found or lead other companies.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $221.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $221.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $290.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $125.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $142.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Organovo, Inc. do?
- Organovo develops regenerative medicine therapies using bioprinting technology to treat serious liver diseases. The company serves the pharmaceutical and biotech sectors with innovative therapeutic approaches based on decades of leadership expertise in life sciences.
- Who are Organovo, Inc.'s investors?
- Organovo, Inc.'s investors include Aurum Venture Partners, Khosla Ventures.